2021
SGNTGT-001: A phase 1 study of SEA-TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies (trial in progress).
Garralda E, Sanborn R, Minchom A, Davar D, Curigliano G, Ribrag V, Mehta A, Foss F, Zain J, Forero-Torres A, Ansell S. SGNTGT-001: A phase 1 study of SEA-TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies (trial in progress). Journal Of Clinical Oncology 2021, 39: tps2657-tps2657. DOI: 10.1200/jco.2021.39.15_suppl.tps2657.Peer-Reviewed Original ResearchAnti-tumor immune responseInhibitory immune checkpoint receptorsRegulatory cell depletionObjective response ratePhase II doseProgression-free survivalDose-limiting toxicityMetastatic solid tumorsPhase 1 studyT cell responsesT cell immunoreceptorImmune checkpoint receptorsImmune cell activationPK-PD correlationsAnti-tumor activityExpansion cohortPrimary endpointSecondary endpointsAdvanced malignanciesAdverse eventsLaboratory abnormalitiesMemory CD8Overall survivalComplete responseNK cells
2004
Mycosis fungoides and the Sézary syndrome
Foss F. Mycosis fungoides and the Sézary syndrome. Current Opinion In Oncology 2004, 16: 421-428. PMID: 15314509, DOI: 10.1097/00001622-200409000-00002.Peer-Reviewed Original ResearchConceptsEarly-stage patientsSézary syndromeMycosis fungoidesTreatment paradigmPeptide-loaded dendritic cellsEvolution of immunotherapyUse of photopheresisClinical prognostic factorsNucleoside analogue therapyReceptor-directed therapyT cell responsesTreatment of patientsNon-Hodgkin lymphomaNovel treatment optionsFurther clinical evaluationNovel therapeutic approachesHistone deacetylase inhibitorsWorld Health OrganizationAnalogue therapySystemic therapyClinical stagingDendritic cellsPrognostic factorsSézary cellsClinical entity